Table 1.
Clinical characteristics of localized PCa study cohorts.
| MDACC-PCa cohort |
AS cohort |
|
|---|---|---|
| Characteristics | N (%) | N (%) |
| Total | 1762 | 393 |
| Age at diagnosis | ||
| Mean(SD) | 61.6 (7.9) | 64.2 (8.3) |
| Tumor Stage (T), N (%) | ||
| T1 | 1,109 (62.94) | 349 (88.8) |
| T2 | 575 (32.63) | 44 (11.2) |
| T3-T4 | 69 (3.92) | 0 |
| Unknown | 9 (0.51) | 0 |
| PSA level at diagnosis, ng/mla,b | ||
| <4 or <2.5 | 442 (25.11) | 89 (22.7) |
| 4–9.9 or 2.5–3.9 | 1,108 (62.95) | 108 (27.5) |
| 10–19.9 or 4–9.9 | 145 (8.24) | 182 (46.3) |
| ≥20 or ≥10 | 65 (3.69) | 14 (3.6) |
| Biopsy-proven GS | ||
| ≤6 | 657 (37.29) | 325 (82.7) |
| 3 + 4 | 647 (36.72) | 60 (15.3) |
| 4 + 3 | 240 (13.62) | 8 (2.0) |
| ≥8 | 218 (12.37) | 0 |
| D’Amico risk group | ||
| Low | 598 (33.94) | 315 (80.2) |
| Intermediate | 829 (47.05) | 73 (18.6) |
| High | 330 (18.73) | 5 (1.3) |
| Not grouped | 5 (0.28) | 0 |
| Disease reclassificationb | ||
| Yes | - | 127 (32.4) |
| No | - | 265 (67.6) |
| Biochemical recurrence | ||
| Yes | 96 (8.14) | - |
| No | 1,084 (91.86) | - |
| Treatment | ||
| Radical prostatectomy | 918 (52.10) | - |
| Radiotherapy | 378 (21.45) | - |
| Surveillance or unknownc | 429 (24.35) | - |
| Otherd | 37 (2.10) | - |
| Follow-up time | ||
| Median(Range) | 47.4 (2.9–125.8) | - |
aDifferent criteria were used to categorize patients by PSA levels between study populations. Retrospective case series: <4 versus 4–9.9 versus 10–19.9 versus ≥20 ng/ml; AS cohort: <2.5 versus 2.5–3.9 versus 4–9.9 versus ≥10 ng/ml.
bPSA information of two patients in MDACC-PCa cohort were missing, while disease reclassification information of one patients in AS cohort was not available.
cPatients undergoing active surveillance/watchful waiting or whose initial treatment information was unavailable.
dCryoablation, high intensity focused ultrasound, transurethral resection of prostate or androgen deprivation therapy.